Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 5;17(8):sfae206.
doi: 10.1093/ckj/sfae206. eCollection 2024 Aug.

Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants

Affiliations

Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants

Frida Welander et al. Clin Kidney J. .

Abstract

Background: Patients with chronic kidney disease (CKD) and atrial fibrillation (AF) on oral anticoagulants (OACs) are at high risk of bleeding. Determinants of major bleeding risk in OAC users with AF and CKD are not well established and available bleeding score systems do not perform well in CKD. This study aims to present risk factors associated with major bleeding in a Swedish cohort of OAC-treated patients with CKD G3-5D.

Methods: We conducted a Swedish register-based cohort study including patients with AF and CKD G3-5D on warfarin or direct OACs (DOACs) between 2009 and 2018. Data were collected from high-quality registers including the Swedish Renal Registry and Auricula, a register for AF and OACs. Risk factors for major bleeding were investigated with Cox regression analysis.

Results: Of 2453 included patients, 59% were on warfarin (time in therapeutic range 67%) and 41% on DOACs. Major bleeding rates were 8.9/100 patient-years. Factors associated with increased bleeding risk were glomerular filtration rate category, G5/5D versus G3 {hazard ratio [HR] 1.92 [95% confidence interval (CI) 1.43-2.56]}, previous gastrointestinal bleeding [HR 1.77 (95% CI 1.39-2.25)], previous other bleeding [HR 1.33 (95% CI 1.09-1.62)], congestive heart failure [HR 1.36 (95% CI 1.11-1.68)], male sex [HR 1.28 (95% CI 1.03-1.60)] and vascular disease [HR 1.35 (95% CI 1.01-1.79)].

Conclusion: Patients with AF and G3-5D on OACs are at a high risk of bleeding. Previous major bleeding and kidney failure are strongly associated with major bleeding. The present study also shows an association between OAC-associated bleeding and male sex, congestive heart failure and vascular disease. Knowledge about determinants of bleeding in advanced CKD is essential when deciding on when to anticoagulate or not.

Keywords: anticoagulants; atrial fibrillation; bleeding; chronic kidney disease; dialysis.

PubMed Disclaimer

Conflict of interest statement

A.S. has received consultancy or lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer. F.W. and H.R. declare no conflicts of interest.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Unadjusted Kaplan–Meier curves for the outcome major bleeding as well as the three types of major bleeding (intracranial, gastrointestinal and other bleeding) during OAC treatment. Graphs presented with years since entry (up to 4 years) on the x-axis and cumulative incidence on the y-axis. At-risk numbers are provided.

Similar articles

References

    1. Hindricks G, Potpara T, Dagres Net al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. - PubMed
    1. De Vriese AS, Caluwé R, Van Der Meersch Het al. . Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021;32:1474–83. - PMC - PubMed
    1. Siontis KC, Zhang X, Eckard Aet al. . Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:1519–29. 10.1161/CIRCULATIONAHA.118.035418 - DOI - PMC - PubMed
    1. Welander F, Renlund H, Dimény Eet al. . Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D. Clin Kidney J 2023;16:835–44. 10.1093/ckj/sfad004 - DOI - PMC - PubMed
    1. Fu EL, Desai RJ, Paik JMet al. . Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study. Am J Kidney Dis 2024;83:293–305.e1. - PubMed

LinkOut - more resources

  NODES
Association 3
twitter 2
USERS 2